The following is a summary of “Risk of severe bacterial infections including TB before and after immediate or deferred ...

The world is facing a new and devastating frontier in the Aids epidemic - THE INDEPENDENT VIEW: Editorial: If the human ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

In 2010, at age 23, Ayu Oktariani learned she was HIV positive. Not only did she lose her husband to AIDS, but during her ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Demonstrators gathered Thursday on the steps of the Department of Health and Human Services (HHS) building for a “die-in” ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

A former top federal health official who served during President Trump’s first term warned that the drastic cuts to the ...

The Russia and Eurasia Program examines the rapid rise in HIV/AIDS cases in Russia and Eurasia and the consequences if the pandemic is left unchecked Until the mid-1990s, Russia and Eurasia had ...